FDA Approves Telix's Pixclara, First FET-PET Imaging Drug for Glioma

The FDA has approved Pixclara (floretyrosine F 18, or 18F-FET), Telix Pharmaceuticals' amino-acid PET imaging drug for glioma — the first FDA-approved FET-PET imaging agent for brain cancer in the United States. The approval, announced September 14, 2026, arrived just after the drug's September 11 PDUFA goal date and closed out a review that included a complete response letter earlier this year.

A diagnostic gap MRI alone can't close

The clinical problem Pixclara addresses is a familiar one in neuro-oncology: after surgery, radiation, or chemotherapy, MRI often cannot reliably tell a physician whether an abnormality on the scan is the tumor progressing or simply tissue changes caused by treatment itself — a phenomenon known as pseudoprogression. Getting that call wrong can mean switching a patient off an effective therapy, or continuing one that has stopped working. FET-PET adds a molecular signal — how much a radiolabeled amino acid tracer is taken up by tumor cells — that MRI's anatomical and perfusion-based views don't directly provide.

That combination is not a novel idea in oncology practice: FET-PET is already named in NCCN Guidelines and other international clinical practice recommendations as a tool for exactly this distinction. What has been missing in the U.S. is an FDA-approved product to perform it. Telix's approval changes that, giving American clinicians a domestically cleared option rather than relying on off-label or investigational use of the tracer.

A resubmission that beat its own deadline

Telix's regulatory path here is itself a useful data point for sponsors managing a diagnostic-drug NDA. The company originally filed the application for TLX101-Px (Pixclara) in August 2024. The FDA responded with a complete response letter asking for additional confirmatory diagnostic performance data — a request that, in imaging-drug reviews, typically concerns how reliably the agent's readout correlates with the clinical truth it claims to detect, rather than a safety finding.

Telix resubmitted the NDA on March 13, 2026, and the FDA accepted that resubmission on April 10, 2026, setting a PDUFA goal date of September 11, 2026. The approval, announced September 14, landed just after that date — a reminder that a goal date is a target for FDA action, not a guaranteed same-day approval, even on a resubmission the agency has already signaled it finds adequate.

“FDA approval of Pixclara will enable broad access in the U.S. to FET-PET imaging, which is already recognized in international clinical practice guidelines.” Kevin Richardson, CEO, Telix Precision Medicine

Frequently asked questions

What did the FDA approve?

Pixclara (floretyrosine F 18, also called 18F-FET), an amino-acid PET imaging drug from Telix Pharmaceuticals. It is indicated for use with PET imaging to help differentiate recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and pediatric patients 1 month of age and older.

Why is this the first of its kind?

FET-PET imaging is already recommended in international clinical practice guidelines, including the NCCN Guidelines, for evaluating glioma. But until this approval, no FET-PET imaging drug had been cleared by the FDA, so U.S. clinicians lacked a domestically approved product for the technique.

What was the path to approval?

Telix originally submitted the NDA for TLX101-Px (Pixclara) in August 2024. The FDA issued a complete response letter requesting additional confirmatory diagnostic performance data. Telix resubmitted the application on March 13, 2026, and the FDA accepted the resubmission on April 10, 2026, assigning a PDUFA goal date of September 11, 2026. The approval was announced September 14, 2026 — just after that goal date.

What problem does it solve for clinicians?

After treatment, MRI often cannot reliably distinguish a glioma that is progressing from tissue changes caused by therapy itself (pseudoprogression). FET-PET adds a molecular read on amino-acid uptake by tumor cells, giving physicians another diagnostic input alongside MRI and other evaluations when that distinction is unclear.